Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 44

Sort by

Sort Order Select

Journal Articles

Efficacy and Safety of Elranatamab in Black Patients with Relapsed/Refractory Multiple Myeloma (RRMM): A Subgroup Analysis of the Magnetismm Studies

Asya Varshavsky-Yanovsky, Yogesh Jethava, Don A. Stevens, Ajay K. Nooka, Patrick J. Stiff, Isabel Perez-Cruz, Eric Leip, Alexander Lesokhin

Blood (2023) 142 (Supplement 1): 3333.

https://doi.org/10.1182/blood-2023-181951

Published: 2023

Journal Articles

Safety of Elranatamab in Patients with Triple-Class Refractory Relapsed/Refractory Multiple Myeloma (RRMM) in Magnetismm-17, a North American Expanded Access Protocol

Nizar J Bahlis, Suzanne Trudel, Christopher Maisel, Lisa X. Lee, Jorge Monge, Claudia Paba Prada, Sarah M. Larson, Guenther Koehne, Yogesh Jethava, Wei Dong Ma, Cristina De Nicolo, Isabel Perez-Cruz

Blood (2023) 142 (Supplement 1): 6737.

https://doi.org/10.1182/blood-2023-189700

Published: 2023

Journal Articles

Efficacy and Safety of Elranatamab in Patients with Relapsed/Refractory Multiple Myeloma Naïve to B-Cell Maturation Antigen (BCMA)-Directed Therapies: Results from Cohort a of the Magnetismm-3 Study

Blood (2022) 140 (Supplement 1): 391–393.

https://doi.org/10.1182/blood-2022-162440

Published: 2022

Journal Articles

Altered Iron Metabolism Is a New Targetable Hallmark for Multiple Myeloma

Can Li, MD, Xuelian Tan, Qierra Brockman, BA, Yogesh Jethava, MBBS,MDFRCPath,MRCP, Marta Chesi, PhD, P. Leif Bergsagel, MD, Fangping Chen, MD PhD, Ivana Frech, DSc, PhD MBA, Fenghuang Zhan, MD PhD

Blood (2019) 134 (Supplement_1): 3059.

https://doi.org/10.1182/blood-2019-123473

Published: 2019

Journal Articles

Targeting NEK2 Induces Cellular Senescence in B-Cell Malignancies through p53-Independent Signaling Pathways

Yuqi Zhu, Ye Yang, PhD, Yogesh Jethava, MBBS,MDFRCPath,MRCP, Ivana Frech, DSc, PhD MBA, Guido J. Tricot, MD PhD, Fenghuang Zhan, MD PhD

Blood (2019) 134 (Supplement_1): 3102.

https://doi.org/10.1182/blood-2019-123815

Published: 2019

Journal Articles

Event-Free Survival at 24 Months Following Autologous Stem Cell Transplant in Diffuse Large B-Cell Lymphoma

Seth M Maliske, MD, Matthew J. Maurer, MS, Carrie A. Thompson, MD, Luis Porrata, MD, Ivana Micallef, MD, Rebecca L. King, MD, Sergei Syrbu, MD PhD, Brian K. Link, MD, Margarida Magalhaes Silverman, MD, Yogesh Jethava, MBBS,MDFRCPath,MRCP, David James J Inwards, MD, Stephen M Ansell, MD PhD, James R. Cerhan, MD PhD, Patrick Johnston, MD PhD, Umar Farooq, MD

Blood (2019) 134 (Supplement_1): 2896.

https://doi.org/10.1182/blood-2019-124579

Published: 2019

Journal Articles

Impact of Absolute Lymphocyte Count at Time of Antithymocyte Globulin on Outcomes of Allogeneic Unrelated Hematopoietic Cell Transplantation with Busulfan and Fludarabine Myeloablative Conditioning

Adithya Chennamadhavuni, MBBS, Kalyan Nadiminti, Lindsay Dozeman, Umar Farooq, MD, Yogesh Jethava, MBBS, MDFRCPath, MRCP, Sarah Mott, MS, Margarida Magalhaes Silverman, MD

Blood (2019) 134 (Supplement_1): 5671.

https://doi.org/10.1182/blood-2019-128186

Published: 2019

Journal Articles

Development of an Easily Accessible Patient-Derived Xenograft (PDX) Mouse Model in Multiple Myeloma

Can Li, MD, Yogesh Jethava, MBBS, MDFRCPath, MRCP, Ivana Frech, DSc, PhD MBA, Fenghuang Zhan, MD PhD

Blood (2019) 134 (Supplement_1): 5538.

https://doi.org/10.1182/blood-2019-121933

Published: 2019

Journal Articles

TRIP13 Modulates Protein Deubiquitination to Promote Myeloma Progression

Can Li, MD, Reinaldo Franqui-Machin, Jiliang Xia, PhD, Gregory S. Thomas, Yogesh Jethava, MBBS,MDFRCPath,MRCP, Fangping Chen, MD PhD, Ivana Frech, DSc, PhD MBA, Guido J. Tricot, MD PhD, Fenghuang Zhan, MD PhD

Blood (2019) 134 (Supplement_1): 854.

https://doi.org/10.1182/blood-2019-123818

Published: 2019

Journal Articles

Risk Factors for Acute Myeloid Leukemia and Myelodysplastic Syndromes in Patients with Multiple Myeloma: An Updated Analysis

Gudbjorg Jonsdottir, MD, Magnus Björkholm, MD PhD, Ingemar Turesson, MD PhD, Malin Hultcrantz, MD PhD, Anna Porwit, MD PhD, Yogesh Jethava, MBBS, MD FRCPath, MRCP, Ola Landgren, MD PhD, Sigurður Yngvi Kristinsson, MD PhD

Blood (2018) 132 (Supplement 1): 4437.

https://doi.org/10.1182/blood-2018-99-111715

Published: 2018

Journal Articles

The Nek2 Genetic Knockout Mouse Model Provides Novel Treatment Strategies in Myeloma and Lymphoma

Li Can, MD, Kalyan Nadiminti, Yuqi Zhu, Yogesh Jethava, MBBS, MD FRCPath, MRCP, Ivana Frech, DSc, PhD MBA, Guido J. Tricot, MD PhD, Fenghuang Zhan, MD PhD

Blood (2018) 132 (Supplement 1): 5612.

https://doi.org/10.1182/blood-2018-99-115099

Published: 2018

Journal Articles

Early Intensive Therapy in Multiple Myeloma Using Tandem Transplantation with Novel Conditioning and Two Years Maintenance: A Single Institution Experience

Kalyan Nadiminti, MD, Christopher Strouse, MD, Praveen Vikas, MD, Lindsay Dozeman, Allyson Schultz, Sarah L Mott, Jillna Claus, Umar Farooq, MD, Margarida Silverman, MD, Michael Tomasson, MD, Fenghuang Zhan, MD PhD, Yogesh Jethava, MBBS, MDFRCPath, MRCP, Guido J. Tricot, MD PhD

Blood (2018) 132 (Supplement 1): 2152.

https://doi.org/10.1182/blood-2018-99-113890

Published: 2018

Journal Articles

A Single Autologous Stem Cell Transplant (ASCT) Followed By Two Years of Post-Transplant Therapy in Recently Diagnosed Elderly Multiple Myeloma (MM) Patients. Safety and Response Results from the Prospective Phase II Trial (NCT01849783)

Kalyan Nadiminti, MD, Christopher Strouse, MD, Praveen Vikas, MD, Lindsay Dozeman, Allyson Schultz, Gabrielle Berns, Jillna Claus, Sarah L Mott, Umar Farooq, MD, Margarida Silverman, MD, Michael Tomasson, MD, Fenghuang Zhan, MD PhD, Yogesh Jethava, MBBS, MD FRCPath, MRCP

Blood (2018) 132 (Supplement 1): 2153.

https://doi.org/10.1182/blood-2018-99-118443

Published: 2018

Journal Articles

Hematopoietic Cell Transplant-Comorbidity Index (HCT-CI) Score Predicts Non-Relapse Mortality (NRM) and Overall Survival (OS) in Multiple Myeloma Patients Undergoing Intensive Preparative Regimen with Autologous Stem Cell Transplantation (ASCT) Followed By Maintenance Therapy Using Novel Agents

Kalyan Nadiminti, MD, Umar Farooq, MD, Lindsay Dozeman, Sarah Mott, MS, Guido J. Tricot, MD PhD, Yogesh Jethava, MBBS,MDFRCPath,MRCP, Margarida Silverman, MD

Blood (2017) 130 (Supplement 1): 3281.

https://doi.org/10.1182/blood.V130.Suppl_1.3281.3281

Published: 2017

Journal Articles

Frequency and Outcome of Clinically Signficant Incidental Findings in Plasma Cell Dyscrasias Patients Undergoing Whole Body FDG PET-CT Scan

Ehsan Shabbir, MD, Sarah L Mott, Lindsay Dozeman, Umar Farooq, MD, Yogesh Jethava, MBBS,MDFRCPath,MRCP, Guido J. Tricot, MD PhD

Blood (2017) 130 (Supplement 1): 5376.

https://doi.org/10.1182/blood.V130.Suppl_1.5376.5376

Published: 2017

Journal Articles

The Interaction of NEK2 with USP7 Causes Resistance to Proteasome Inhibitor in Multiple Myeloma

Reinaldo Franqui-Machin, Mu Hao, PhD, Bai Hua, Zhimin Gu, PhD, Xin Zhan, Hongwei Xu, Hasem Habelhah, Yogesh Jethava, MBBS,MDFRCPath,MRCP, Lugui Qiu, MD, Ivana Frech, DSc, PhD MBA, Guido J. Tricot, MD PhD, Fenghuang Zhan, MD PhD

Blood (2017) 130 (Supplement 1): 593.

https://doi.org/10.1182/blood.V130.Suppl_1.593.593

Published: 2017

Journal Articles

C-Reactive Protein Monitoring Can Predict Neutropenic Fever during Autologous Hematopoietic Stem Cell Transplantation for Mutliple Myeloma

Vidya Kollu, MD, Sarah L Mott, Lindsay Dozeman, Fnu Rafiullah, MD, Umar Farooq, MD, Yogesh Jethava, MBBS,MDFRCPath,MRCP, Guido J. Tricot, MD PhD

Blood (2017) 130 (Supplement 1): 5529.

https://doi.org/10.1182/blood.V130.Suppl_1.5529.5529

Published: 2017

Journal Articles

Effect of Dosing Bortezomib According to Adjusted Body Surface Area in Multiple Myeloma

Susan Fajardo, PharmD, Marie Sirek, PharmD, Yogesh Jethava, MBBS,MDFRCPath,MRCP, Guido J. Tricot, MD PhD

Blood (2017) 130 (Supplement 1): 5406.

https://doi.org/10.1182/blood.V130.Suppl_1.5406.5406

Published: 2017

Journal Articles

Does Your Smoldering Myeloma Patient Need Treatment? Evidence Based Recommendations

Rafiullah, MD, Umar Zahid, MD, Irbaz Bin Riaz, MDMMSc, Ali McBride, PharmD,MS, Ahmad Iftikhar, MD, Yogesh Jethava, MBBS,MDFRCPath,MRCP, Guido J. Tricot, MD PhD, Faiz Anwer, MD

Blood (2017) 130 (Supplement 1): 5431.

https://doi.org/10.1182/blood.V130.Suppl_1.5431.5431

Published: 2017

Journal Articles

A Single Autologous Stem Cell Transplant (ASCT) Followed By Two Years of Post-Transplant Therapy Is Safe in Older Recently Diagnosed Multiple Myeloma (MM) Patients. Preliminary Results from the Prospective Phase II Trial (NCT01849783)

Kalyan Nadiminti, MD, Lindsay Dozeman, Annick Tricot, Allyson Schultz, Sheila Ouverson, Fenghuang Zhan, MD PhD, Margarida Silverman, MD, Guido J. Tricot, MD PhD, Yogesh Jethava, MBBS,MDFRCPath,MRCP

Blood (2017) 130 (Supplement 1): 4543.

https://doi.org/10.1182/blood.V130.Suppl_1.4543.4543

Published: 2017

NARROW

Efficacy and Safety of Elranatamab in Black Patients with Relapsed/Refractory Multiple Myeloma (RRMM): A Subgroup Analysis of the Magnetismm Studies

Safety of Elranatamab in Patients with Triple-Class Refractory Relapsed/Refractory Multiple Myeloma (RRMM) in Magnetismm-17, a North American Expanded Access Protocol

Efficacy and Safety of Elranatamab in Patients with Relapsed/Refractory Multiple Myeloma Naïve to B-Cell Maturation Antigen (BCMA)-Directed Therapies: Results from Cohort a of the Magnetismm-3 Study

Altered Iron Metabolism Is a New Targetable Hallmark for Multiple Myeloma

Targeting NEK2 Induces Cellular Senescence in B-Cell Malignancies through p53-Independent Signaling Pathways

Event-Free Survival at 24 Months Following Autologous Stem Cell Transplant in Diffuse Large B-Cell Lymphoma

Impact of Absolute Lymphocyte Count at Time of Antithymocyte Globulin on Outcomes of Allogeneic Unrelated Hematopoietic Cell Transplantation with Busulfan and Fludarabine Myeloablative Conditioning

Development of an Easily Accessible Patient-Derived Xenograft (PDX) Mouse Model in Multiple Myeloma

TRIP13 Modulates Protein Deubiquitination to Promote Myeloma Progression

Risk Factors for Acute Myeloid Leukemia and Myelodysplastic Syndromes in Patients with Multiple Myeloma: An Updated Analysis

The Nek2 Genetic Knockout Mouse Model Provides Novel Treatment Strategies in Myeloma and Lymphoma

Early Intensive Therapy in Multiple Myeloma Using Tandem Transplantation with Novel Conditioning and Two Years Maintenance: A Single Institution Experience

A Single Autologous Stem Cell Transplant (ASCT) Followed By Two Years of Post-Transplant Therapy in Recently Diagnosed Elderly Multiple Myeloma (MM) Patients. Safety and Response Results from the Prospective Phase II Trial (NCT01849783)

Hematopoietic Cell Transplant-Comorbidity Index (HCT-CI) Score Predicts Non-Relapse Mortality (NRM) and Overall Survival (OS) in Multiple Myeloma Patients Undergoing Intensive Preparative Regimen with Autologous Stem Cell Transplantation (ASCT) Followed By Maintenance Therapy Using Novel Agents

Frequency and Outcome of Clinically Signficant Incidental Findings in Plasma Cell Dyscrasias Patients Undergoing Whole Body FDG PET-CT Scan

The Interaction of NEK2 with USP7 Causes Resistance to Proteasome Inhibitor in Multiple Myeloma

C-Reactive Protein Monitoring Can Predict Neutropenic Fever during Autologous Hematopoietic Stem Cell Transplantation for Mutliple Myeloma

Effect of Dosing Bortezomib According to Adjusted Body Surface Area in Multiple Myeloma

Does Your Smoldering Myeloma Patient Need Treatment? Evidence Based Recommendations

A Single Autologous Stem Cell Transplant (ASCT) Followed By Two Years of Post-Transplant Therapy Is Safe in Older Recently Diagnosed Multiple Myeloma (MM) Patients. Preliminary Results from the Prospective Phase II Trial (NCT01849783)

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only